The Gamble Behind a Takeover of Kenvue, Maker of Tylenol
Potentially huge legal issues are hovering over Kenvue. But Kimberly-Clark, which agreed to buy it for $40 billion, appears to think they’re manageable. Source link
Track the latest in business and finance—from market trends and economic updates to startup stories and global trade analysis.
Potentially huge legal issues are hovering over Kenvue. But Kimberly-Clark, which agreed to buy it for $40 billion, appears to think they’re manageable. Source link
President Trump wants pharmaceutical production to return to the United States. A shuttered factory in Louisiana shows how hard that will be for generic medicines. Source link
The Defense Department’s new press policy led to an exodus of traditional journalists. Supporters of the president have stepped in. Source link
Niche is the latest company to help families predict what they might pay. If only colleges would do more. Source link
Poland and other countries across Europe that found economic success in an era of collaboration are now facing a crumbling of international alliances. Source link
Plus: How much does a reader owe a big tech company while planning to depart? Source link
Prepared pasta sold at grocery chains across the country, including Albertsons and Trader Joe’s, were recalled after 27 people in 18 states became ill, federal health officials said. Source link
In a deal valued at $4 billion, Boyu Capital will acquire a stake in the coffee giant’s 8,000 stores in China. Source link
Mr. Musk’s supporters say he may quit if shareholders don’t approve a trillion-dollar package. Some investors say it’s excessive and would give him too much sway. Source link
The consumer products giant reached a $40 billion deal to buy Kenvue, the maker of Tylenol, despite a barrage of unproven claims from President Trump and others that use of the pain reliever during pregnancy can cause autism. Source link